The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 12, 2024
Filed:
Jun. 13, 2019
Applicant:
Amphista Therapeutics Ltd, England, GB;
Inventors:
Alessio Ciulli, Dundee, GB;
Andrea Testa, Dundee, GB;
Scott Hughes, Dundee, GB;
Steven Peter Butcher, Dundee, GB;
Assignee:
AMPHISTA THERAPEUTICS LIMITED, London, GB;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/60 (2017.01); A61K 31/277 (2006.01); A61K 31/351 (2006.01); A61K 31/404 (2006.01); A61K 31/407 (2006.01); A61K 31/4184 (2006.01); A61K 31/423 (2006.01); A61K 31/428 (2006.01); A61K 31/4375 (2006.01); A61K 31/44 (2006.01); A61K 31/47 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/5355 (2006.01); A61K 31/551 (2006.01); A61K 47/55 (2017.01); C07D 417/14 (2006.01); C07D 495/14 (2006.01);
U.S. Cl.
CPC ...
A61K 47/60 (2017.08); A61K 31/277 (2013.01); A61K 31/351 (2013.01); A61K 31/404 (2013.01); A61K 31/407 (2013.01); A61K 31/4184 (2013.01); A61K 31/423 (2013.01); A61K 31/428 (2013.01); A61K 31/4375 (2013.01); A61K 31/44 (2013.01); A61K 31/47 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/5355 (2013.01); A61K 31/551 (2013.01); A61K 47/55 (2017.08); C07D 417/14 (2013.01); C07D 495/14 (2013.01);
Abstract
The invention provides for bifunctional molecules comprising an Rpn11 binding partner and a target protein binding partner. A bifunctional molecule according to the invention binds to Rpn11 and to the target protein, thereby facilitating degradation of the target protein bound to the target protein binding partner. The invention also provides for use of a bifunctional molecule for preventing or treating disease.